Buscar
Resultados de la búsqueda
- NGcGM3/VSSP y nimotuzumab en pacientes con cáncer de mama triple negativo
-
... “Inmunoterapia con NGcGM3/VSSP y nimotuzumab en pacientes con cáncer de mama triple negativo metastásico”. ... NGcGM3/VSSP, nimotuzumab, cáncer de mama triple negativo ...
Ensayos Clínicos - CIM - 22/12/2016 - 11:38am
- Effectiveness and Safety of Nimotuzumab for the treatment of patients with glioma tumors
-
... of the Effectiveness and Safety of Monoclonal Antibody HR3(Nimotuzumab)for the treatment of patients with high grade glioma tumors. ... Nimotuzumab: 200 mg intravenous (antecubital vein) in a volume of 250 ml ...
Clinical Trials - CIMAB - 17/07/2015 - 10:47am
- Efectividad y seguridad del Nimotuzumab en pacientes con tumores gliales.
-
... la efectividad y seguridad del anticuerpo monoclonal hR3(Nimotuzumab)para el tratamiento de pacientes con tumores gliales de alto grado ... claves: Nimotuzumab,Tumores Gliales. ...
Ensayos Clínicos - CIMAB - 17/07/2015 - 10:47am
- Study of intensive pediatric pharmacovigilance of nimotuzumab for the treatment of malignant glioma tumors.
-
... pediatric pharmacovigilance of monoclonal antibody nimotuzumab for the treatment of malignant glioma tumors ... Scheme 1: Surgery + Radiotherapy (54-60 Gy) + Nimotuzumab + Chemotherapy (Cisplatin + Cyclophosphamide, procarbazine; ...
Clinical Trials - CIMAB - 14/08/2014 - 4:34pm
- Farmacovigilancia intensiva en pediatría de nimotuzumab para el tratamiento de tumores gliales malignos
-
... intensiva en pediatría del anticuerpo monoclonal nimotuzumab para el tratamiento de tumores gliales malignos. ... claves: nimotuzumab,tumores gliales malignos, tumores cerebrales pediátricos ...
Ensayos Clínicos - CIMAB - 14/08/2014 - 4:34pm
- CIMAVax EGF in Lung Cancer in PHC. Phase IV
-
... treatment with EGF therapeutic vaccine CIMAvax and / or Nimotuzumab (therapeutic monoclonal antibody hR3). 2. Patients with chronic ...
Clinical Trials - CIM - 05/08/2014 - 3:18pm
- CIMAVaxEGF en Cáncer Pulmón en APS
-
... tratamiento con la vacuna terapéutica CIMAvax EGF y/o Nimotuzumab (Anticuerpo monoclonal terapéutico hR3). 2. Pacientes con ...
Ensayos Clínicos - CIM - 05/08/2014 - 3:17pm
- Racotumomab,Nimotuzumab or Docetaxel in the treatment of the advanced non-small cell lung cancer.
-
... patients with advanced NSCLC treated with Racotumomab or Nimotuzumab, vs Docetaxel after first line treatment oncospecific. ... general condition permits. Group 2 (experimental arm) : Nimotuzumab mAb (200 mg) intravenous (antecubital vein), in 250 ml of saline ...
Clinical Trials - CIM - 26/05/2014 - 3:06pm
- Racotumomab,Nimotuzumab o Docetaxel para el tratamiento de cancer de pulmon de celulas no pequeñas avanzado.
-
... en pacientes con CPCNP avanzado tratados con Racotumomab o Nimotuzumab, vs Docetaxel después de la primera línea de tratamiento ... general del paciente lo permita. Grupo 2 (estudio): AcM Nimotuzumab (200 mg) por vía endovenosa (vena ante cubital), en 250 ml de ...
Ensayos Clínicos - CIM - 26/05/2014 - 2:59pm
- Phase II / III. Nimotuzumab in patients with triple-negative breast cancer.
-
... for the evaluation of the efficacy and safety of using Nimotuzumab in patients with triple-negative breast cancer. Phase II / III. ... arm): Chemotherapy (CT) + CT a dose metronomic + Nimotuzumab: 200 mg intravenously in 250 ml of isotonic saline for 30 minutes. ...
Clinical Trials - CIM - 23/05/2014 - 2:16pm